<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02657473</url>
  </required_header>
  <id_info>
    <org_study_id>54939</org_study_id>
    <nct_id>NCT02657473</nct_id>
  </id_info>
  <brief_title>Inhaled Nebulized Tobramycin in Non-cystic Fibrosis Bronchiectasis</brief_title>
  <acronym>BATTLE</acronym>
  <official_title>Long-term Inhaled Nebulized Tobramycin in Patients With Non-cystic Fibrosis Bronchiectasis. A Randomized Placebo Controlled Trial. The BATTLE Study Bronchiectasis And Tobramycin SoluTion InhaLation ThErapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical Center Alkmaar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical Center Alkmaar</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of tobramycin inhalation solution (TIS)
      once daily compared tot placebo in patients with non-CF bronchiectasis. The primary endpoint
      is a reduction of exacerbations of the disease during the treatment period. Next to this
      parameter the investigators expect to show a significant beneficial effect on lung function
      parameters, QoL, bacterial load of pathogens in sputum and tobramycin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      See uploaded study protocol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 13, 2016</start_date>
  <completion_date type="Actual">December 13, 2019</completion_date>
  <primary_completion_date type="Actual">December 13, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>. In present study the value of maintenance TIS will be investigated in patients with non-CF bronchiectasis colonized by different bacterial species sensitive for tobramycin.
Objective: The primary outcome of the study is a 50% reduction in exacerbation rate in patients using maintenance TIS (OD). Secondary outcome parameters are lung function (FEV1, FVC), QoL (QOL-B), LTRI-VAS, Leicester cough score, bacterial load in sputum and tobramycin resistant pathogens.
Study design: A randomised, double blind placebo controlled, multicenter study. Study population: Patients aged ≥ 18-year-old with confirmed bronchiectasis by (HR)CT and at least two exacerbations during previous 12 months.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Non-CF Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>TIS 300mg once daily</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tobramycin inhalation solution (TIS) 300mg once daily for at least 9 months and up to 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo once daily</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline 0.9% inhalation solution 300mg once daily for at least 9 months and up to 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tobramycin inhalation solution</intervention_name>
    <arm_group_label>TIS 300mg once daily</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline 0.9% inhalation solution</intervention_name>
    <arm_group_label>Placebo once daily</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. The presence of chronic respiratory symptoms such as cough, dyspnoea, expectoration of
             sputum

          3. Confirmed non-CF bronchiectasis by (HR)CT

          4. Documented history of at least 2 pulmonary exacerbations treated with courses of
             antibiotics within 12 months before inclusion.

          5. No course of antibiotics or maintenance antibiotics (except for macrolides) 1 month
             prior to the start of the study.

          6. Minimal one documented sputum or BAL-fluid culture with gram-negative bacteria or
             S.aureus within 12 months.

          7. Growth of protocol defined pathogens in sputum at screening visit sensitive to
             tobramycin

          8. Tolerance of inhaled tobramycin

        Exclusion Criteria:

          1. Any exacerbation within the month prior to the start of the study

          2. Diagnosis of cystic fibrosis

          3. Active allergic bronchopulmonary aspergillosis (ABPA)

          4. Any oral, IV or inhaled antibiotics (except for macrolides) within 1 month prior to
             the start of the study

          5. Any IV or IM corticosteroids or change in oral corticosteroids (&gt; 10 mg) within 1
             month prior to the start of the study

          6. Any change/start treatment regimens macrolides, hypertonic saline, inhaled mannitol or
             other mucolytics, corticosteroids within 1 month prior to the start of the study

          7. Change in physiotherapy technique or schedule within 1 month prior to the start of the
             study

          8. Severe immunosuppression or active malignancy

          9. Active tuberculosis

         10. Chronic renal insufficiency (eGFR &lt; 30 ml/min), use of loop diuretics

         11. Have received an investigational drug or device within 1 month prior to the start of
             the study

         12. Serious or active medical or psychiatric illness

         13. Pregnancy and child bearing

         14. History of poor cooperation or non-compliance

         15. Unable to use nebulizers

         16. Allergic for tobramycin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wim G. Boersma, Dr.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical Center Alkmaar</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North West Clinics</name>
      <address>
        <city>Alkmaar</city>
        <state>Noord-Holland</state>
        <zip>1815JD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spaarne Gasthuis</name>
      <address>
        <city>Hoofddorp</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMCU</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>January 13, 2016</study_first_submitted>
  <study_first_submitted_qc>January 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 15, 2016</study_first_posted>
  <last_update_submitted>December 13, 2019</last_update_submitted>
  <last_update_submitted_qc>December 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical Center Alkmaar</investigator_affiliation>
    <investigator_full_name>W.G.Boersma</investigator_full_name>
    <investigator_title>Dr.MD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/73/NCT02657473/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

